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Since 1982 the departments of cardiology and Clinical Pharmacology of Groningen
investigate the role of the renin angiotensin system in cardiac disease. More recently by
employing molecular techniques, the departments address fundamental genetic mechanisms
by which disturbances of the RAS can contribute to cardiovascuiar disease. This thesis
describes the role of a genetically increased activity of ACE and the angiotensin II (AT,)
receptor in cardiovascular disease by answering two main questions:
1. Are genetic polymorphisrns around the genes forACE, ar.rd the angiotensin II receptor
associated with cardiovascular disease?
2. tif i l l  experimentally increased expression of the genes for ACE and the angiotensin II
(AT1) receptor induce cardiovascular dysfunction?
The epiderniologic-genetic results of question I :rre described in Section II, while the
experiment:rl results of question 2 are described in sectior-r l l l .
Section II
At the beginning of this thesis it was sti l l  unknown whether the association that was fbund
between the ATrR (1166) polyrnorphisrn, essential hypertension and increased coronary
artery vasoconstriction was based on a diffbrence in angiotensin II responsiveness.
\We found (chapter 3), in internal mammary arteries of patients with the CC genotype
an incre:rsed response to angiotensin l l, explainir"rg a possible mechanism between this
polymorphism ancl cardiovascular abr.rormalities.
Many known risk factors, that increase angiotensin l l responsiveness by modulating
ATIR expression, also impair endothelium dependent relaxation. In chapter 4 we show
that high angiotensir.r II responsiveness inversely correlates to endothelium dependent
relaxation in internal mamm:rry :rrteries of patients with established coronary artery disease.
These findings suggest that :rny type of increased angiotensin I I responsiveness may adversely
aflcct endothclial function possible leading to cardiovascular morbidity.
In chapter 5 we louncl that the combirratiorr of ACE DD (higher ACE activity) and
,{l-rR CC genotype is a risk fhctol for recurrent ischcmic events in males with established
CAD. -I 'his increased risk was not due to an increased progression rate of coronary lesions.
\7e speculate that increascd plaque instabil ity by incrcascd local RAS activity could be one
, r l - t l t c . r r r r ses  wh l  rhesc  p r t i c r t t r  r e  a l  i nc rca \ed  r i sk  [ o r  r ccu r ren t  i schemic  even ts .
Chapter 6 provides evidence ftrr genotypc depcndcnt induction of plasrna ACE activity
after CABG, which can be prevented by ACE inhibit ion. Thc modulating effect of the
ACtl I/D ge ne polymorphism to regr-rlatory factors might be of interest in the unclerstanding
of the relationship fbund between this polymorphism, RAS :rctivation, cardiovascular
pathologies, and the inter-individual variabil itv in response to ACE inhibitors. That genetic
alterations not only can modih' disease but also can modi{y the efficacy of treatmcnt of thc
disease is described in chapter 7. \7e assessed in a subset of the Regression Growth Evaluation
Statin Study (REGRESS) whether the ACE I/D gene polymorphism modifies the beneficial
effect of pravastatin on the atherosclerotic process. \ffe lound that although the lipid lowering
effect of pravastatin was sirnilar in the three genotype groups pravastatin was less effective
in halting the progression of coronary atherosclerosis in the D/D genotype group. This
slr€l€lests that the process of atherosclerosis i  less re:rdily:rttenuated by l ipid-lowering
treatme nt in homoz.ygous c:rrriers of the ACE deletion allele .
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these components do r.rot affect the heart, but t l-rat more robust changes in activity are
necded. Furthermore, many of the association studies provide conflicting d:rta, probably
due to thc low absoh,rte risk conferred bv the RAS genotvpes, ethnic diversity, the often
retrospective or cross-sectional nature of the analyses, the lorv prevalence of the polymorphism
:rncl variations in population stabil ity (founder effects). 'fherefore, althoueh we do find a
ftrnctional elfect of Lroth the ACE and Af1R polymorphisms, rve have to challenge the
clinical reievance of these polymorphisms. The now known polymorphisms of the RAS
onlv confer:r l imited risk in cardiovascul:rr disease. However they do further enlighten new
aspects or.r the RAS. In the experinrental part of this thesis rte shor",ed that genetic alteratior.rs
can it.rfluence the efficacy of treatrnent. Future studies should now focus on how genetic
variations in the RAS can modi$' the efficacy of tre2ltmeltt. Only rvith this knowledge we
can reversc the trcatment of cardiovascular disorders from a population and evidence-based
approach, towards a tailored therapy to fit individLral profiles.
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